Longevity.Technology UNLOCKED

GLP‑1 Gene Therapy: A One‑Time Fix for Obesity & Diabetes? | Longevity News Roundup — Week 21, 2026

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: https://partners.fatty15.com/UNLOCKED [https://partners.fatty15.com/UNLOCKED] ---------- In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick examine pancreatic cancer immunotherapy, GLP-1 gene therapy, immune system rebuilding, cardiovascular plaque reversal and microbiome medicine. * MatterBio filed its first IND application for Lm-LLO-TT, an engineered Listeria-based therapy targeting pancreatic ductal adenocarcinoma. Pending FDA clearance, the company plans a Phase 1/2a study evaluating safety, dosing and early efficacy in advanced pancreatic cancer patients resistant to conventional immunotherapy. * Fractyl Health received European approval to begin a first-in-human Phase 1/2 trial of RJVA-001, GLP-1 gene therapy for obesity and type 2 diabetes. The therapy uses endoscopic ultrasound-guided pancreatic delivery to program beta cells to produce GLP-1 in response to meals rather than relying on repeated injections. * Ossium Health presented clinical trial data showing successful engraftment using cryopreserved bone marrow collected from deceased organ donors. Researchers believe the banking platform could eventually simplify bone marrow transplantation logistics and expand future immune system renewal applications. * Cyclarity shared new progress on therapies targeting 7-ketocholesterol, an oxidized cholesterol molecule linked to plaque instability and chronic arterial inflammation. Rather than slowing plaque growth, the company aims to physically remove toxic cholesterol deposits already embedded within blood vessel walls. * Microbiotica reported positive Phase 1b MELODY-1 trial data for MB097, a microbiome therapy containing nine bacterial strains combined with KEYTRUDA in advanced melanoma patients. The therapy showed successful gut engraftment and encouraging signals that microbiome modulation may help overcome immunotherapy resistance. * The episode also explored health equity in longevity medicine with Poonam Desai ahead of The Longevity Show. Discussions focused on sex-specific medicine, unequal access to longevity care and the risks of building precision health systems around biased clinical data. ---------- News & References: * ‘Rebuilding the human immune system is possible’ → https://longevity.technology/news/rebuilding-the-human-immune-system-is-possible/ [https://longevity.technology/news/rebuilding-the-human-immune-system-is-possible/] * Fractyl Health to begin EU trials for one-time weight loss gene therapy → https://longevity.technology/news/fractyl-health-to-begin-eu-trials-for-one-time-weight-loss-gene-therapy/ [https://longevity.technology/news/fractyl-health-to-begin-eu-trials-for-one-time-weight-loss-gene-therapy/] * Matter Bio takes pancreatic therapy to clinic → https://longevity.technology/news/matter-bio-takes-pancreatic-therapy-to-clinic/ [https://longevity.technology/news/matter-bio-takes-pancreatic-therapy-to-clinic/] * New data suggests plaque damage can be cleared → https://longevity.technology/news/new-data-suggests-plaque-damage-can-be-cleared/ [https://longevity.technology/news/new-data-suggests-plaque-damage-can-be-cleared/] * Microbiome medicine moves past wellness into clinics → https://longevity.technology/news/microbiome-medicine-moves-past-wellness-into-clinics/ [https://longevity.technology/news/microbiome-medicine-moves-past-wellness-into-clinics/] * ‘Equity in longevity is the entire ballgame’ → https://longevity.technology/news/equity-in-longevity-is-the-entire-ballgame/ [https://longevity.technology/news/equity-in-longevity-is-the-entire-ballgame/]

Valter Longo: Can Short Fasting Cycles Regenerate the Body?

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: fatty15.com/UNLOCKED [fatty15.com/UNLOCKED] ---------- Guests: Valter Longo Professor and Director at USC Longevity Institute Instagram: https://www.instagram.com/prof_valterlongo/ [https://www.instagram.com/prof_valterlongo/] Website: https://valterlongo.com/ [https://valterlongo.com/] ---------- What if a five-day diet could reset metabolism, regenerate tissue, and challenge decades of nutrition dogma? Phil Newman and Dr. Nina Patrick sit down with Valter Longo, USC Longevity Institute researcher and architect of the fasting mimicking diet, to explore how short, periodic fasting cycles may interact with aging biology, insulin signaling, and tissue regeneration. Together they break down how the fasting mimicking diet differs from water fasting and simple calorie restriction, and why its plant based, low protein, low sugar, and high fat composition is designed to maintain protection while still triggering nutrient sensing pathways. Longo explains how in clinical and preclinical data, repeated cycles have shown improvements in insulin resistance, reductions in diabetes medication use by 60 to 70% in some cohorts, and measurable shifts in metabolic biomarkers compared to Mediterranean diet controls. The conversation also explores mechanistic findings, including autophagy activation peaking around day five in human studies, stem cell associated regeneration signals, and embryonic like gene expression patterns observed in multiple organ systems. In animal models, these cycles have been associated with pancreatic regeneration, kidney repair after induced damage, and normalization of cholesterol and glucose regulation. In this episode, you’ll learn: * Autophagy activation and peak biological signaling observed around day five in human fasting mimicking protocols * Clinical trials in diabetes showing 60 to 70% reduction in medication use within one year in some populations * Animal studies showing reversal of severe metabolic dysfunction with monthly fasting mimicking cycles * Protein restriction and mTOR IGF-1 signaling pathways repeatedly linked with lifespan extension across multiple species * Risk discussion around prolonged fasting triggering energy conserving metabolic adaptation states If you want to understand how structured fasting protocols may interact with aging pathways, metabolic disease, and regenerative biology, this episode connects clinical evidence with evolutionary and mechanistic frameworks shaping modern longevity science. Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping human healthspan.

Can Longevity Disrupt Hospitals From Within? — Longevity News Roundup — Week 20, 2026

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: https://partners.fatty15.com/UNLOCKED [https://partners.fatty15.com/UNLOCKED] ---------- In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GLP-1 drugs in progressive MS, Executive Health as a gateway to longevity care, AI-assisted skin regeneration, lab-grown red blood cells, and convergence in aging biomarkers. * Neuraly’s NLY01 dosed its first Phase 2 patient with progressive MS in the 120-person, 96-week TAGMS trial. Instead of tracking relapse rates, researchers will use MRI-measured brain atrophy as the primary endpoint to determine whether the GLP-1 receptor agonist can slow neurodegeneration after inflammation is controlled. * Biograph’s six-hour executive assessment compresses what they describe as three months of diagnostics into a single visit. Advanced imaging, biomarker panels, cardiac testing, biological age metrics, and cancer screening are bundled into one experience followed by a personalized action plan. * ROKIT Healthcare presented one to two-year follow-up data showing sensory restoration, minimal scarring, functional recovery, and zero cancer recurrence after AI-assisted autologous skin reconstruction. The platform uses a patient’s own fat-derived cells combined with AI-guided bioprinting to recreate tissue that behaves like original skin. * Hospitals are recognizing that prevention-focused longevity care could erode revenue from late-stage cardiometabolic and surgical interventions. At the same time, they already possess the imaging, labs, multidisciplinary teams, and care coordination required to deliver structured midlife risk assessment programs. * Scarlet Therapeutics raised $4 million in seed funding after demonstrating that lab-grown red blood cells survive in circulation as long as donor-derived cells. The company is developing applications that include universal transfusion supply, therapeutic carrier cells, and engineered red blood cells designed for enhanced biological function. * Steve Horvath argues that apparent biomarker chaos is narrowing toward a smaller set of aging measures that consistently predict mortality, disease risk, and functional decline. This convergence is critical for trials, clinics, and employer programs that need reliable endpoints to justify prevention strategies. ---------- News & References: * GLP-1 drug enters trial for progressive multiple sclerosis → https://longevity.technology/news/glp-1-drug-enters-trial-for-progressive-multiple-sclerosis/ [https://longevity.technology/news/glp-1-drug-enters-trial-for-progressive-multiple-sclerosis/] * Executive Health program condenses three months of testing into six hours → https://longevity.technology/news/executive-health-program-condenses-three-months-of-testing-into-six-hours/ [https://longevity.technology/news/executive-health-program-condenses-three-months-of-testing-into-six-hours/] * AI regenerative medicine targets skin recovery → https://longevity.technology/news/ai-regenerative-medicine-targets-skin-recovery/ [https://longevity.technology/news/ai-regenerative-medicine-targets-skin-recovery/] * Hospitals confront longevity’s quiet disruption → https://longevity.technology/news/hospitals-confront-longevitys-quiet-disruption/ [https://longevity.technology/news/hospitals-confront-longevitys-quiet-disruption/] * Scarlet raises $4m as lab-grown blood matches donor cell survival → https://longevity.technology/news/scarlet-raises-4m-as-lab-grown-blood-matches-donor-cell-survival/ [https://longevity.technology/news/scarlet-raises-4m-as-lab-grown-blood-matches-donor-cell-survival/] * ‘We are not at consensus but we are at convergence’ → https://longevity.technology/news/we-are-not-at-consensus-but-we-are-at-convergence/ [https://longevity.technology/news/we-are-not-at-consensus-but-we-are-at-convergence/]

Can You Reverse Cognitive Decline?

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: fatty15.com/UNLOCKED [fatty15.com/UNLOCKED] ---------- Guests: Dr Henry Mahncke CEO of BrainHQ from Posit Science Instagram: https://www.instagram.com/brainhq_app/ [https://www.instagram.com/brainhq_app/] Website: https://www.brainhq.com/ [https://www.brainhq.com/] Dr Majid Fotuhi Johns Hopkins Professor and Author of The Invincible Brain Instagram: https://www.instagram.com/dr_fotuhi/ [https://www.instagram.com/dr_fotuhi/] Website: https://drfotuhi.com/ [https://drfotuhi.com/] ---------- What if cognitive decline is not a fixed trajectory but a reversible biological state shaped by how we train the brain? In this episode of Longevity Technology Unlocked, Dr. Nina Patrick and Phil Newman are joined by Dr. Henry Mahncke, CEO of Posit Science, and Dr. Majid Fotuhi, Johns Hopkins affiliated neurologist and author of The Invincible Brain. The discussion explores a shift in neuroscience thinking, from viewing cognitive aging as inevitable decline to seeing it as a modifiable process driven by neuroplasticity, attention, and lifestyle. They break down why dementia and cognitive decline are increasingly being reframed as outcomes influenced by multiple modifiable systems. Dr. Mahncke explains how decades of brain plasticity research, including early cochlear implant studies, helped establish that the adult brain remains capable of change. Dr. Fotuhi adds a clinical framework built around five pillars of brain health, combining cognitive training with exercise, sleep, diet, and stress control as a unified intervention strategy for cognitive resilience. Across both perspectives, the emphasis is on adaptive, challenging training that continuously engages attention and processing speed as a driver of broad brain plasticity rather than isolated cognitive skills. In this episode, you’ll learn: * How speed-based cognitive training is linked to long-term reductions in dementia risk * Why attention and processing speed are central drivers of neuroplasticity * How structured 12-week programs can improve memory and cognitive performance * The role of lifestyle pillars like sleep, exercise, and diet in brain resilience * Why mindset and perceived cognitive limits may influence brain adaptation If you want to understand how neuroplasticity reshapes aging trajectories, this episode connects clinical neuroscience with real-world interventions for brain healthspan. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

The Future of Longevity Medicine — Longevity News Roundup — Week 19, 2026

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: https://partners.fatty15.com/UNLOCKED [https://partners.fatty15.com/UNLOCKED] ---------- In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine multi-target Alzheimer's therapy, sugar glycation in aging, personalized CRISPR for Parkinson's, Longevity.Technology partnerships, FDA real-time trials, and peptide platforms. * Longevity.Technology partners with AND Capital Ventures to combine DLT intelligence platform with funding for healthspan startups. It maps hallmarks, biomarkers, and revenue trajectories to scale longevity firms from data to investment. This scaffolds the ecosystem like oncology, signaling maturation into an asset class. * Annovis Bio's Buntanetap oral pill reduces production of multiple neurotoxic proteins like amyloid, tau, and alpha-synuclein by targeting mRNA translation machinery. This upstream approach outperforms single-target amyloid drugs, offering a practical pill over infusions. * Estée Lauder research reveals sugar-induced glycation in skin cells triggers inflammation, senescence, and elasticity loss beyond collagen stiffening. Published in International Journal of Molecular Sciences, it links metabolic sugar exposure to systemic aging in vessels and organs. * Scribe Therapeutics' CRISPR platform, with STX-1150 data, advances personalized gene editing for Parkinson's, repairing genetic defects in neurons for dopamine restoration. Precise delivery shows strong safety and efficiency signals. * FDA pilots real-time cloud-based trials with AstraZeneca and Amgen, streaming data for faster safety signals and approvals. Aimed at accelerating development, it suits longevity's slow endpoints via validated biomarkers like frailty indices. * LifespanningRX launches clinician-guided peptide programs for clinics, handling prescriptions, compounding, and shipping amid RFK Jr.-era FDA easing. With $500K funding, it taps recovery and longevity stacks demand via compliant platforms. Raises standards but risks hype without outcome tracking. ---------- News & References: * Longevity.Technology and AND Capital Ventures launch partnership → https://longevity.technology/news/longevity-technology-and-and-capital-ventures-launch-partnership/ [https://longevity.technology/news/longevity-technology-and-and-capital-ventures-launch-partnership/ ] * Buntanetap gains ground in new Alzheimer’s trial results → https://longevity.technology/news/buntanetap-gains-ground-in-new-alzheimers-trial-results/ [https://longevity.technology/news/buntanetap-gains-ground-in-new-alzheimers-trial-results/] * Sugar’s hidden role in skin aging revealed → https://longevity.technology/news/sugars-hidden-role-in-skin-aging-revealed/ [https://longevity.technology/news/sugars-hidden-role-in-skin-aging-revealed/] * LifespanningRx launches partner program for peptide therapy → https://longevity.technology/news/lifespanningrx-launches-partner-program-for-peptide-therapy/ [https://longevity.technology/news/lifespanningrx-launches-partner-program-for-peptide-therapy/] * FDA’s real-time trial push could transform medicine – if they work → https://longevity.technology/news/fdas-real-time-trial-push-could-transform-medicine-if-they-work/ [ https://longevity.technology/news/fdas-real-time-trial-push-could-transform-medicine-if-they-work/] * Scribe highlights CRISPR advances and STX-1150 data at ASGCT, EAS → https://longevity.technology/news/scribe-highlights-crispr-advances-and-stx-1150-data-at-asgct-eas/ [https://longevity.technology/news/scribe-highlights-crispr-advances-and-stx-1150-data-at-asgct-eas/]